A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
Prasugrel Hydrochloride has been studied across 7 research domains including ❤️ Cardiovascular, 🔥 Metabolic, 🧠 Focus & Attention, 💊 Pain, ⏳ Longevity & Aging. The primary research focus is ❤️ Cardiovascular with 30% of studies addressing this area.
The following compounds share molecular targets with Prasugrel Hydrochloride, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Prasugrel Hydrochloride is generated deterministically from 44 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.